trending Market Intelligence /marketintelligence/en/news-insights/trending/NPBHG3YMivtOXHcZeBuAaQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Axim Biotechnologies to acquire oncology research company Sapphire Biotech

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Axim Biotechnologies to acquire oncology research company Sapphire Biotech

Axim Biotechnologies Inc. signed a binding term sheet to acquire Sapphire Biotech Inc., an oncology research and development company.

Sapphire develops proprietary therapies for inhibiting growth and spread of cancer. The company is also developing diagnostics for early cancer detection, response to treatment and recurrence monitoring.

As part of the agreement, San Diego-based Axim Biotechnologies will acquire all of Sapphire's outstanding capital and assume all its outstanding debt.

The parties plan to enter into a definitive deal by Feb. 28.

Axim will gain Sapphire's portfolio of technologies through the deal, as well as the ability to develop new proprietary molecules, the company said in a filing.

Axim develops and produces cannabinoid-based pharmaceutical and nutraceutical products.